Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, we've managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.

Our mature, cohesive team of nine partners has been working together for over six years. Our investment professionals have over 250 years of combined experience in operational, financial, and scientific roles in the life sciences industry. We have played significant leadership roles in a number of both public and private life sciences companies, including acting as founders and directors of start-up ventures as well as executive officers of both large cap pharmaceutical and biotechnology companies. The combination of our broad experience in the capital markets and access to a substantial network of scientific and industry expertise gives Bay City Capital a unique perspective and practical approach to creating and maximizing shareholder value.

We pursue a broad spectrum of investment opportunities across the various life sciences sectors and with companies at all stages of development. Through many years of experience in venture investing, our team has developed a systematic process based on thoughtful selection, comprehensive due diligence, and active investment management.

We invest in life sciences companies where our operational, financial, and scientific expertise can benefit company management. We work closely with our portfolio companies as true partners in their growth, creating value over the long term. We assist management in recruiting and retaining key management and scientific advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with clinical trial design and execution. We provide ongoing access to a substantial network of industry and academic leaders, experienced advisors, and a significant amount of capital and other resources as needed.

Typically, we are the lead or co-lead investor and maintain board representation.

Bay City Capital’s life sciences venture capital funds (including co-investments from Pritzker Family business interests) represent approximately $1,450 million in capital invested in 55 companies:

Bay City Capital Fund I	Formed in 1997	$150,000,000
Bay City Capital Fund II	Formed in 1999	$200,000,000
Bay City Capital Fund III	Formed in 2001	$250,000,000
Bay City Capital Fund IV	Formed in 2004	$350,000,000
Bay City Capital Fund V	Formed in 2007	$500,000,000

We have invested in a diverse group of life sciences companies, across all stages of the product lifecycle. Our portfolio includes companies focusing on biopharmaceuticals and drug discovery, as well as medical devices and diagnostics. Identified as opportunities based on our evaluation of market conditions and the overall competitive environment, our investments have ranged from seed investing to early, mid-, and late-stage, as well as select public investing.

Bay City Capital also serves as the Investment Advisor to the $111 million North American Nutrition and Agriculture Fund (NANAF). Formed in 1999, NANAF, along with its European and Australian sister funds, operates under the umbrella of the Gilde Food & Agribusiness Fund. NANAF invests in high potential companies that are at the forefront of developing new technologies that will benefit human health and agribusiness.

Bay City Capital also has entered into a joint venture with Birchmere Ventures whereby Bay City Capital serves as a co-sponsor of Birchmere Ventures III, representing $43 million in aggregate committed capital. Birchmere Ventures III is an early-stage life sciences and technology investment fund based in Pittsburgh and focused on investing in companies in the Mid-Atlantic region.

The employees of Bay City Capital have also made significant personal commitments to all these investment funds and corresponding portfolio companies, with over $65 million invested to date.